Maravai Beats on Q3 Revenue Growth, Lifts Full-Year Guidance
MRVI has more than doubled off its 52-week low of $2.545.
Summary
Maravai posted Q3 2026 revenue of $45.9 million, up 10.1% year-over-year, with TriLink up 11.8% and Cygnus up 7.5%. The bottom line improved sharply: net loss narrowed to $(24.0) million from $(45.1) million a year ago, and Adjusted EBITDA swung to $5.8 million from $(10.8) million. Management raised full-year 2026 revenue guidance to $212.0 million to $216.0 million from $205.0 million to $215.0 million, and lifted Adjusted EBITDA guidance to $40.0 million to $42.0 million from $33.0 million to $35.0 million. The quarter extends the margin recovery seen in Q2, when gross margin doubled to 40.1% on restructuring benefits. Four Discovery mRNA customers moved to clinical-stage GMP this quarter, which supports the TriLink pipeline story.
At the time of this announcement, MRVI was trading at $7.73 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $2.55 to $9.42. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.